Continuous fiber support barrier for engineered vascular networks

By using electrospinning technology and post-manufacturing processing to form a vascular network surrounded by a continuous fibrous membrane, the lack of basement membrane structure in bioengineered vascular networks was solved, achieving stability and reduced immune response under high-pressure environments, and simulating the density and interface control of body tissues.

CN119013055APending Publication Date: 2024-11-22IVIVA MEDICAL INC
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202380034255.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-04-21
Filing Date
2023-04-20
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

Existing technologies struggle to create continuous basement membrane structures in bioengineered vascular networks, resulting in a lack of stable substrates for the endothelial cell layer and an inability to regulate the interaction between the immune system and engineered tissue grafts.

Method used

A vascular network surrounded by a continuous fibrous membrane is manufactured using electrospinning technology. With the use of appropriate sacrificial materials and post-manufacturing treatments such as compression, annealing, and chemical cross-linking, a fibrous basement membrane with high mechanical strength and biocompatibility is formed to surround the vascular network and provide barrier function.

Benefits of technology

It achieves stability of vascular networks under high-pressure environments, reduces the immunogenicity of implanted cells, and simulates the density of body tissues and ease of host remodeling, providing interface control between vascular networks and surrounding tissues.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119013055A_ABST
    Figure CN119013055A_ABST
Patent Text Reader

Abstract

Disclosed herein are devices comprising one or more channels defining a lumenal space, wherein the lumenal space is defined by an inner wall of a fibrous basement membrane material; and methods of making and using the same.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Related Applications

[0002] This application claims the benefit of U.S. Provisional Application No. 63 / 333,107, filed on April 20, 2022, and U.S. Provisional Application No. 63 / 333,533, filed on April 21, 2022, the entire contents of which are hereby incorporated by reference. Background Art

[0003] Bioengineering of human tissue and organ transplants holds promise for addressing the shortage of donated organs and providing new tissue for the treatment of conditions that cannot be easily transplanted. However, achieving this goal will likely require reconstructing the native endothelial structure, particularly the continuous basement membrane.

[0004] Current methods for fabricating engineered vascular networks do not allow for the creation of a continuous basement membrane structure around the channels. This structure is important for normal vascular function because it provides a stable substrate for the endothelial cell layer while also providing a solid physical barrier to cellular infiltration, aneurysms, and pressure-induced rupture. In the case of blood-contacting bioengineered grafts intended for ex vivo perfusion or implantation via vascular anastomosis, a continuous engineered basement membrane structure could provide a means to modulate or inhibit the interaction of the innate immune system with engineered tissue grafts.

[0005] It is necessary to create an engineered vascular network with a well-defined architecture that incorporates a continuous basement membrane structure within the graft. Summary of the invention

[0006] Applicants have unexpectedly discovered that by utilizing electrospinning and suitable sacrificial materials, a vascular network surrounded by a continuous fiber membrane can be manufactured. This type of vascular network has great advantages because it can withstand higher pressures than other engineered vascular networks, making it suitable for applications with higher pressures in vivo. Further, this type of vascular network can be designed to reduce or eliminate the immunogenicity of cells implanted inside the network. In addition, this type of vascular network enables the use of surrounding materials with lower density, which better simulate some body tissues (e.g., epithelial tissue, soft tissue), and can be easily reshaped by the host in some applications.

[0007] Some aspects of the present invention relate to a kind of equipment, it includes one or more passages limiting luminal space, wherein the luminal space is limited by the inner wall of fiber basement membrane material.In some embodiments, the one or more passages form a vascular channel network.In some embodiments, the vascular channel network has a first end configured to be in fluid communication with a fluid supply port (fluidsupply) and a second end configured to be connected in fluid communication with a fluid outlet fluid.

[0008] In some embodiments, the device further includes a scaffold material contacted with the outer wall of the fiber basement membrane material. In some embodiments, the scaffold material includes one or more additional vascular channel networks, which are optionally limited by the inner wall of the fiber basement membrane material. In some embodiments, the scaffold material includes cells or bulk tissue. In some embodiments, in the absence of the fiber basement membrane material support, the mechanical strength of the scaffold material is not enough to limit the luminal space.

[0009] In some embodiments, the inner wall of the fibrous basement membrane material, when implanted in a subject, inhibits or prevents the subject's immune response to cells and other materials in the luminal space.

[0010] In some embodiments, the fibrous basement membrane material comprises pores of sufficient size to allow diffusion of one or more bio-related molecules. In some embodiments, the one or more channels can withstand an internal pressure of at least 60 mmHg. In some embodiments, the vascular channel network can withstand an internal pressure of at least 60 mmHg.

[0011] In some embodiments, the fibrous basement membrane material includes one or more of gelatin, gelatin complex, collagen, fibrin, chitosan, nitrocellulose, polylactic acid, polycaprolactone, polyethylene glycol, polyethylene glycol diacrylate, or other biopolymers, polymers, or decellularized tissues or extracellular matrices that have been liquefied or homogenized.

[0012] In some embodiments, the fibrous basement membrane material comprises electrospun fibers. In some embodiments, the fibrous basement membrane material comprises electrospun fibers, the electrospun fibers comprising a first component selected from the group consisting of polycaprolactone, polyethylene glycol, and polyethylene glycol diacrylate, and a second component selected from the group consisting of gelatin, collagen, and fibrin, and wherein the fibrous basement membrane has a thickness of 0.5-30 microns.

[0013] In some embodiments, the fiber base film material has been subjected to one or more post-manufacturing treatments selected from compression, annealing, chemical crosslinking, stretching, drawing, heat treatment and solvent welding, thus compared with the fiber base film material that does not accept one or more of these post-manufacturing treatments, the treated fiber base film material is endowed with enhanced mechanical properties. In some embodiments, the enhanced mechanical properties are selected from the group consisting of enhanced tensile strength, enhanced tensile modulus, enhanced wear resistance, enhanced thermal stability, enhanced elongation at break, enhanced hardness, enhanced crystallinity and a combination thereof. In some embodiments, post-manufacturing treatment includes solvent welding. In some embodiments, solvent welding is carried out in the presence of the pressure imparted by the opposing support substrate. In some embodiments, post-manufacturing treatment includes a combination of heat treatment and the pressure imparted by the opposing support substrate.

[0014] In some embodiments, the device is implanted in a subject. In some embodiments, the device is located outside the subject's body.

[0015] In some embodiments, the luminal space comprises one or more cells selected from endothelial cells, epithelial cells, mesenchymal cells, induced pluripotent stem cell-derived cells, endocrine cells, and stromal cells.

[0016] In some embodiments, the device is configured to function as an artificial kidney, pancreas, lung, myocardium, liver, spleen, small intestine, large intestine, neural tissue, skeletal muscle, composite tissue, adipose tissue, bone tissue, or skin. BRIEF DESCRIPTION OF THE DRAWINGS

[0017] This patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee.

[0018] Figure 1 is an image of a sacrificial material (water-soluble polyvinyl alcohol (PVA)) fabricated into a hierarchical vascular pattern surrounded by electrospun nanofibers of (PCL) and gelatin.

[0019] Figure 2 is a SEM image (cross section) of the nanofibrous membrane deposited around the printed Pluronic F127 vascular pattern.

[0020] Figure 3 The left sub-image is an image of the printed sacrificial material being encapsulated during the electrospinning process. Figure 3 The right panel is an image of the construct embedded in a bulk gelatin material and perfused with dye.

[0021] Figure 4 is a graph showing the burst pressure of vascular networks with and without fiber support. N=3.

[0022] Fig. 5a-d depicts the characteristics of electrospun fiber membrane wrappings saturated with pure acetone and subjected to compression for a duration of 5 minutes. Fig. 5a depicts a scaffold formed by compressing an acetone-saturated fiber membrane on a sacrificial substrate, wherein the compression lasts for a duration of 5 minutes. Fig. 5b is an SEM image of a cross-section of the treated fiber membrane. Fig. 5c is an SEM image of the treated fiber membrane surface. Fig. 5d depicts the same scaffold with channels perfused with dye after treatment.

[0023] Figures 6a-d depict the properties of fiber membrane wraps saturated with pure acetone and subjected to compression for a duration of 1 minute. Figure 6a depicts a scaffold formed by compressing an acetone-saturated fiber membrane on a sacrificial substrate, wherein the compression comprises a duration of 5 minutes. Figure 6b is an SEM image of a cross-section of the treated fiber membrane. Figure 6c is an SEM image of the surface of the treated fiber membrane. Figure 6d depicts the same scaffold with channels perfused with dye after treatment.

[0024] Figures 7a-d depict the properties of fiber membrane wraps sprayed with a small volume of pure acetone and subjected to compression for a duration of 5 minutes. Figure 7a depicts a scaffold formed by compressing a sacrificial substrate covered with a fiber membrane sprayed with a small volume of pure acetone, wherein the compression comprises a duration of 5 minutes. Figure 7b is an SEM image of a cross-section of the treated fiber membrane. Figure 7c is an SEM image of the surface of the treated fiber membrane. Figure 7d depicts the same scaffold with channels perfused with dye after treatment.

[0025] Figures 8a-d depict the sequential assembly of a large tissue scaffold using water-soluble polyurethane as a sacrificial material. Figure 8a depicts a large tissue scaffold comprising a membrane having a water-soluble polyurethane channel pattern printed thereon, which is undergoing close-range electrospinning for membrane wrapping. Figure 8b depicts the accumulation of electrospun fibers on the printed water-soluble polyurethane pattern, where the location of fiber accumulation is affected by the collector electrode. Figures 8c and 8d are SEM images of cross-sections of the membrane and water-soluble polyurethane pattern after close-range electrospinning at magnifications of 160 times and 120 times, respectively.

[0026] Figures 9a-b depict the properties of the membrane wrap after having been subjected to a light compression of about 3-8 psi plus a heat treatment including heating to about 55°C for 18 hours. Figure 9a is a SEM image of a cross section of a heat-treated electrospun membrane surrounding a water-soluble polyurethane pattern taken at 55X magnification. Figure 9b is a SEM image of a cross section of a heat-treated electrospun membrane surrounding a water-soluble polyurethane pattern taken at 180X magnification. DETAILED DESCRIPTION

[0027] Provided herein are devices and compositions for providing a continuous barrier layer with controlled composition between a vascular network and an engineered tissue material or a graft. Some embodiments relate to an engineered vascular network made of a sacrificial material, which is used as a substrate for making a basement membrane layer, which is continuous and, for example, completely surrounds the vascular network and provides separation from any additional tissue material placed outside the vascular lumen. This membrane is fibrous, porous, and mechanically strong, allowing fluids and molecules of a certain size to pass through the membrane while also preventing molecules, particles, cells, and other materials larger than the desired size from passing through.

[0028] Applicants have unexpectedly discovered that by utilizing electrospinning and suitable sacrificial materials, a vascular network surrounded by a continuous fiber membrane can be manufactured. This vascular network has great advantages because it can withstand higher pressures than other engineered vascular networks, making it suitable for applications with higher pressures in vivo. Further, this vascular network can be designed to reduce or eliminate the immunogenicity of cells implanted (migrated) inside the network. In addition, this vascular network enables the use of lower density surrounding materials to better simulate some body tissues (e.g., epithelial tissue, soft tissue), and is easily reshaped by the host in some applications.

[0029] Some aspects of the present invention relate to a device comprising a tissue scaffold containing a vascular network surrounded by a continuous biocompatible fiber basement membrane layer. In some embodiments, the continuous biocompatible fiber basement membrane layer provides a complete barrier that prevents cells (e.g., blood cells) within the vascular network from contacting cells outside the network.

[0030] Another aspect of the present invention relates to a device with one or more channels that limit luminal space. The luminal space can be limited by the inner wall of the fiber basement membrane material. The cross-sectional profile and longitudinal profile of the one or more channels can cover a variety of shapes and structures. In one embodiment, the cross-sectional profile of the one or more channels has a cylindrical, approximately cylindrical or partially flattened cylindrical shape. The longitudinal profile of the one or more channels includes a linear configuration, a nonlinear configuration, or a combination of a linear configuration and a nonlinear configuration, and adopts a bifurcated, non-bifurcated or networked configuration. In a preferred embodiment, the longitudinal profile of the one or more channels is nonlinear and includes a curved configuration, such as an S-curve configuration. In addition, the cross-sectional profile of the one or more channels defines a diameter between about 6 μm and 10 cm, more preferably between about 15 μm and 5 cm, and most preferably between about 60 μm and 1.5 cm. The cross-sectional diameter of the one or more channels can remain constant, or can change on part or all of the longitudinal axes of the one or more channels.

[0031] In a preferred embodiment, the combination of cross section and longitudinal profile causes one or more channels to be configured to simulate the lumen naturally present in mammals. For example, the one or more channels are configured to simulate the substructure or the combination of substructures of the cardiovascular system of mammals. Therefore, in one embodiment, the one or more channels can be configured to simulate the aorta, artery, arteriole, arteriovenous anastomosis, capillary, arteriolar branch, capillary bed, venule, vein or their combination. In a particularly preferred embodiment, the one or more channels include at least two channels, and the at least two channels are configured to form a vascular channel network.

[0032] In some embodiments, the vascular channel network has a first end configured to be communicated with a fluid supply port (fluid supply) and a second end configured to be connected in communication with a fluid outlet. Under this configuration, the vascular channel network is used in vitro or in vitro in a laboratory, hospital or other research and clinical environment, or is used in vivo and directly implanted in a subject. When the vascular channel network is configured to be used in vitro or in vitro, the fluid supply port, the fluid outlet, or the fluid supply port and the fluid outlet both include one or more pumps for starting or maintaining the fluid movement in the vascular channel network or are communicated with the one or more pump fluids. As a non-limiting example, the pump used in the present invention is a commonly used pump in a laboratory or clinical environment, including a piston pump, a diaphragm pump, a peristaltic pump, a syringe pump, a pneumatic pump, a microfluidic pump, an infusion pump, a vacuum pump and a combination thereof. Further, the fluid supply port, the fluid outlet, or the fluid supply port and the fluid outlet both include one or more valves for regulating the fluid flow in the vascular channel network or are communicated with the one or more valve fluids. As non-limiting examples, valves encompassed by the present invention are valves commonly used in laboratory or clinical environments and include isolation valves, fluid control valves, metering valves, check valves, and special purpose valves, each of which may be classified as a gate valve, ball valve, pinch valve, diaphragm valve, needle valve, butterfly valve, plug valve, or other type of valve. Optionally, the present invention may include one or more sensors for determining flow rate, temperature, pressure, etc.

[0033] In some embodiments, the equipment has the support material contacted with the outer wall of fiber basement membrane material.In some embodiments, support material contains one or more extra vascular channel networks, and this vascular channel network is optionally limited by the inwall of fiber basement membrane material.In some embodiments, support material can contain multilayer material, and each layer of material in this multilayer material is solid, semisolid or limits one or more passages or channel network therein.In some embodiments, at least one passage or channel network of at least one support layer and at least one other passage or channel network of at least one other support layer or the channel interface limited by the outer wall of fiber basement membrane material.In preferred embodiments, the interface between the passage of different support layers is to be communicated via direct fluid, or is through the interface of fiber membrane.

[0034] In some embodiments, the scaffold material comprises cells or bulk tissue. The type of cells and bulk tissues inoculated and placed on or in the scaffold is not particularly limited, and comprises any cell or bulk tissue type listed herein. In a preferred embodiment, the cell comprises stem cell, endothelial cell, cardiomyocyte, parietal epithelial cell, hepatocyte, bile duct cell, stellate cell, adipocyte, osteoblast, osteocyte, osteoclast, enterocyte, goblet cell, enteroendocrine cell, Paneth cell, microfold cell, goblet cell, clump cell, or is present in kidney, pancreas, lung, myocardium, liver, spleen, small intestine, large intestine, nervous tissue, skeletal muscle, composite tissue, adipose tissue, bone tissue or other cells in skin.

[0035] In some embodiments, the scaffold material has insufficient mechanical strength to define a luminal space without the support of a fibrous basement membrane material.

[0036] In some embodiments, the inner wall of the fibrous basement membrane material, when implanted in a subject, inhibits or prevents the subject's immune response to cells and other materials in the luminal space.

[0037] In some embodiments, the fiber base membrane material comprises pores of sufficient size to allow one or more bio-related molecules to diffuse. The pore size diameter of the pores in the nanofiber membrane can be any suitable size and is not limited. In one embodiment, the average or median pore size diameter is about 0.05 to about 0.6 μm. In another embodiment, the average or median pore size diameter is about 0.05 μm, 0.1 μm, 0.15 μm, 0.2 μm, 0.25 μm, 0.3 μm, 0.35 μm, 0.4 μm, 0.45 μm, 0.5 μm, 0.55 μm or about 0.6 μm. The porosity (P) of the nanofiber membrane is preferably about 0.05 μm, 0.1 μm, 0.15 μm, 0.2 μm, 0.25 μm, 0.3 μm, 0.35 μm, 0.4 μm, 0.45 μm, 0.5 μm, 0.55 μm or about 0.6 μm. nm ) is calculated by dividing the void volume (V v ) divided by the total volume of the nanofiber membrane measured (V Tvm ) obtained (P = V v / V Tvm * 100%), can be any suitable porosity and is not limited. In some embodiments, the porosity is at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or more. In other embodiments, the porosity is between 20-80%, 30-70% or 40-60%.

[0038] In some embodiments, the one or more channels are capable of withstanding an internal pressure of at least 60 mmHg. In another embodiment, the one or more channels are capable of withstanding an internal pressure of at least 80 mmHg, 100 mmHg, 150 mmHg, 200 mmHg, 250 mmHg, 300 mmHg, 350 mmHg, 400 mmHg, 450 mmHg, 500 mmHg, 550 mmHg, or at least 600 mmHg.

[0039] In some embodiments, the vascular channel network is capable of withstanding an internal pressure of at least 60 mmHg. In another embodiment, the vascular channel network is capable of withstanding an internal pressure of at least 80 mmHg, 100 mmHg, 150 mmHg, 200 mmHg, 250 mmHg, 300 mmHg, 350 mmHg, 400 mmHg, 450 mmHg, 500 mmHg, 550 mmHg, or at least 600 mmHg.

[0040] In some embodiments, the fibrous basement membrane material includes one or more of gelatin, gelatin complex, collagen, fibrin, chitosan, nitrocellulose, polylactic acid, polycaprolactone, polyethylene glycol, polyethylene glycol diacrylate, or a biopolymer, polymer, or a decellularized tissue or extracellular matrix that has been liquefied or homogenized.

[0041] In some embodiments, the fibrous basement membrane material includes electrospun fibers formed by a binary, ternary, quaternary or quinary material mixture. Particularly preferred mixtures include a binary mixture of collagen and polycaprolactone. In a particularly preferred embodiment, collagen is in the form of bovine, porcine or fish gelatin with a molecular weight of 15-400 kDa. In some embodiments, the gelatin will have a bloom value of 30-300, a bloom value of 40-100, a bloom value of 100-200, or a bloom value of 200-280. In addition, the gelatin is cross-linked. In another preferred embodiment, the polycaprolactone used to form electrospun fibers in the fibrous basement membrane has a molecular weight of 10-100 kDa, 25-80 kDa or 30-60 kDa. The single material used in the binary mixture exists in a ratio range of 1:10 to 10:1, preferably 1:4 to 4:1, or more preferably 1:2 to 2:1. In a particularly preferred embodiment, the individual materials in the binary mixture are present in a 1:1 ratio.

[0042] The thickness of the fiber base membrane is not particularly limited and will vary according to a variety of factors including the final use of the device. In some embodiments, the fiber base membrane has a thickness of 0.5-30 μm, a thickness of 3-25 μm or a thickness of 10-20 μm. When the fiber base membrane is designed for use under high pressure, the fiber base membrane will be configured to have an increased thickness and will have a thickness of 10-30 μm. On the contrary, when the fiber base membrane is configured to be used under low or medium pressure, or if it is necessary to increase the elasticity of the membrane, the fiber base membrane is configured to have a lower thickness and will have a thickness of 0.5-20 μm.

[0043] In some embodiments, the device is implanted in a subject. In some embodiments, the device is configured to facilitate surgical anastomosis with natural tissue that defines a pore or luminal space. In a preferred embodiment, the device is attached to an artery, vein, renal collecting duct, bronchioles, endocrine ducts, small intestine, or large intestine fluid communication. In another embodiment, the implanted device can serve as an artificial organ.

[0044] In some embodiments, the device is located outside the subject's body. When the device is configured for in vitro use, the device is directly or indirectly attached to the natural tissue of the limited pore or luminal space in the subject and is in fluid communication. In another embodiment, the device is supported or maintained by the outer surface of the subject's body. In yet another embodiment, the device is independent and placed on a horizontal surface or otherwise fixedly or removably attached to an external support near the subject. In another embodiment, the device serves as an external artificial organ.

[0045] In some embodiments, the luminal space has one or more cells. These cells are not particularly limited and can include any cell described herein. In one embodiment, the one or more cells are endothelial cells, epithelial cells, mesenchymal cells, cells derived from induced pluripotent stem cells, endocrine cells or stromal cells. In a preferred embodiment, the luminal space comprises 2 different cells, 3 different cells, 4 different cells, or 5 or more different cells.

[0046] In some embodiments, the device is configured to serve as an artificial mammalian organ. In preferred embodiments, the device is configured to serve as an artificial kidney, pancreas, lung, myocardium, liver, spleen, small intestine, large intestine, neural tissue, skeletal muscle, composite tissue, adipose tissue, bone tissue or skin.

[0047] In some embodiments, this biocompatible fiber basement membrane layer serves as the border between tissue scaffold endothelial region and other regions, and these other regions may have their own lumen and channel network (kidney, lung etc.) or may be simple bulk tissue (muscle etc.).This layer also provides mechanical support for vascular network, and prevents the adverse events such as aneurysm or rupture caused due to excessive pressure, which is a major challenge for engineered vascular network.In some embodiments, except the mechanical support provided by biocompatible fiber basement membrane layer, this layer also provides the controlled interface between vascular fluid and surrounding tissue.Therefore, in some embodiments, by controlling the porosity and composition of biocompatible fiber basement membrane layer, it is possible to regulate or prevent adverse interactions or influences, such as immune response.This is essentially a packaging strategy of an engineered vascular network, which provides a barrier between host and graft tissue at vascular basement membrane.

[0048] In some embodiments, a low immunogenic endothelium is provided inside a tissue scaffold, and the remaining tissue in the scaffold is isolated from the immune system by a biocompatible fibrous basement membrane layer, thereby achieving a low immune tissue graft or extracorporeal device.

[0049] Some aspects of the present disclosure relate to the manufacture of a single continuous membrane or multiple fiber membranes that surround a sacrificial material in the form of a vascular channel network. These membranes are made of fibers, preferably nanofibers manufactured by electrospinning. Electrospinning is known to those skilled in the art. See Xue et al., Chem. Rev. 2019, 119, 8, 5298–5415, and Teo et al., Nanotechnology 17 (2006) R89–R106, both of which are incorporated herein by reference. Fibers are preferably manufactured by direct electrospinning onto sacrificial materials, alternatively by manufacturing and subsequent deposition or encapsulation steps, so that they create porous fiber membranes along the entire sacrificial material that defines the vascular channel network.

[0050] In some embodiments, electrospinning is carried out near the substrate / collector plate to be coated with electrospun fibers. The distance between the tip and the collector plate in some embodiments is less than 15 centimeters, less than 12 centimeters, less than 10 centimeters, less than 9 centimeters, less than 8 centimeters, less than 7 centimeters, less than 6 centimeters, less than 5 centimeters, less than 4 centimeters, less than 3 centimeters or less than 2 centimeters. In some embodiments, the diameter of the internal pores of the tip, the feed rate of the fiber precursor solution or the melt, and / or the concentration of the polymer in the precursor solute or the melt are reduced to produce a fiber with a smaller diameter. In addition, the applied voltage can be adjusted to reduce the diameter of the fiber formed, such as by increasing the stretching or drawing of the precursor solution or melt sprayed before deposition on the collector substrate. In some embodiments, the volatility and other spinning parameters of any solvent used to dissolve the fiber precursor material are carefully considered to ensure that correct fiber formation and deposition are achieved in the finished fiber film. In certain embodiments, reducing the diameter of the fiber causes the solvent in the precursor solution to evaporate, or the precursor melt is cooled and hardened, and then arrives at the sacrificial substrate / collector plate as a solid fiber. This may be particularly important when the distance between the tip and the sacrificial substrate / collector plate is reduced or very small, as required by certain embodiments of the invention. In alternative embodiments, the feed rate, needle aperture size, and applied voltage are selected to provide semi-solid fibers that anneal to each other when deposited on the substrate / collector plate, thereby reducing the duration of post-manufacturing processing steps, or even allowing post-manufacturing processing to be eliminated entirely.

[0051] In some embodiments, the fiber diameter is less than 10 μm, less than 9 μm, less than 8 μm, less than 7 μm, less than 6 μm, less than 5 μm, less than 4 μm, less than 3 μm, less than 2 μm or less than 1 μm. In some embodiments, most of the fibers present in the fiber membrane are nanofibers with a diameter of 950 nm or less, 800 nm or less, 600 nm or less, 450 nm or less, or 200 nm or less. In some embodiments, most of the fibers in the fiber membrane are nanofibers with a diameter between about 100 nm and 750 nm, between about 100 nm and 500 nm, or between about 250 nm and 800 nm. In some embodiments, the fiber membrane comprises a fiber with a diameter greater than 950 nm, greater than 2 μm, greater than 3 μm, greater than 4 μm, greater than 5 μm or greater. In some embodiments, the diameter of the electrospun fiber is at least 5 μm, at least 6 μm, at least 7 μm, at least 8 μm, at least 9 μm or greater.

[0052] In some embodiments, the manufacture of the device disclosed herein does not involve forming a porous fiber membrane directly on a sacrificial substrate by electrospinning or any other means. Instead, in some embodiments, a porous fiber membrane is formed and then manipulated alone or in combination with other fiber membranes to form one or more channels defining a luminal space. In some embodiments, the one or more porous fiber membranes are manipulated to form a vascular channel network by contacting one or more fiber membranes with one or more channel templates. In a preferred embodiment, this contact is carried out under conditions suitable for inducing a permanent morphological change in the shape of the one or more templates to simulate the one or more porous membranes. Conditions suitable for inducing permanent morphological changes in the one or more porous fiber membranes include contacting in the presence of one or more of the following: elevated temperature, compressive force, and one or more solvents. In some embodiments, the condition includes applying a compressive force sufficient to stretch or pull the fiber membrane around the one or more templates. In a preferred embodiment, at least two conditions exist simultaneously to induce the one or more porous fiber membranes to change in permanent morphology after contacting the one or more templates. In a preferred embodiment, the one or more templates include a sacrificial substrate deposited directly on the fiber membrane. In some embodiments, the sacrificial substrate is deposited onto a substrate that is suitable for immediate release of the sacrificial substrate once the porous fibrous membrane is contacted therewith or applied thereto.

[0053] In some embodiments, the initial fabrication of the electrospun fiber membrane is followed by post-fabrication processing. In some embodiments, post-fabrication processing includes, but is not limited to, one or more of compression, annealing, chemical cross-linking, stretching / pulling, and solvent welding.

[0054] In some embodiments, post-manufacturing treatments may be performed at temperatures between 20-22° C. or above 22° C. In some embodiments, post-manufacturing steps are performed below the glass transition temperature (Tg) of one, two, or all of the materials used to form the fiber membrane, such as at least 5° C., 10° C., 15° C., 20° C., 30° C., or more below the glass transition temperature.

[0055] In certain embodiments, the post-manufacturing step is an annealing performed at a temperature approximately equal to the glass transition temperature of the material used to form the fiber membrane. For the purposes of this application, approximately equal to the glass transition temperature (Tg) is defined as the published glass transition temperature of the material ±5°C, or ±5% of the published Tg, whichever provides a smaller temperature range. In some embodiments, the post-manufacturing step is performed at a temperature between the glass transition temperature and the melting temperature of the material used to form the fiber membrane. It should be understood by those of ordinary skill in the art that when the temperature is raised above the glass transition temperature, the appropriate post-manufacturing processing time should be carefully selected to ensure that the porosity of the membrane is not destroyed due to the large amount of melting of the fiber membrane.

[0056] In some embodiments, the fiber membrane is subjected to a post-manufacturing step at a temperature greater than 25° C., 30° C., 35° C., 40° C., 45° C., 50° C., 55° C., 60° C., 65° C., 70° C., 75° C., 80° C., 85° C., 90° C., 100° C., 125° C., 150° C., 160° C., 170° C., 180° C. or more. In some embodiments, the post-manufacturing step is performed for a period of 1 second, 5 seconds, 10 seconds, 15 seconds, 30 seconds, 45 seconds, 1 minute, 2 minutes, 3 minutes, 4 minutes, 5 minutes, 6 minutes, 7 minutes, 8 minutes, 9 minutes, 10 minutes, 20 minutes, 30 minutes, 45 minutes, or 1 hour. In certain embodiments, it is desired that post-manufacturing processing be performed for longer time periods, including 1.5 hours, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 15 hours, 16 hours, 17 hours, 18 hours, 19 hours, 20 hours, 25 hours, 1 day, 2 days, 3 days or more.

[0057] In some embodiments, the post-manufacturing annealing step includes applying compression to facilitate wrapping the sacrificial substrate with the fiber membrane, as described herein. In some embodiments, applying compression at elevated temperatures facilitates better or faster bonding or annealing of the fibers. In some embodiments, the post-manufacturing annealing and compression steps are performed at a temperature between 120-180°C, 40-70°C, 45-65°C, 50-60°C, or 53-57°C for 11-25 hours, 13-22 hours, 15-20 hours, or 17-19 hours. In certain preferred embodiments, the compression and annealing steps are performed at about 55°C for about 18 hours.

[0058] The pressure amplitude used in the compression step is not particularly limited, as long as it is sufficient to promote the bonding or annealing of the fibers at their intersections while protecting the fiber membrane or substrate to which the pressure is applied from damage. In some embodiments, compression is applied by placing the fiber membrane and the substrate manufactured thereon between two opposing release substrates, the size, shape and hardness of the release substrate allowing sufficient force to be applied to induce the bonding or welding of the fibers without damaging the fiber membrane or substrate to which the force is applied. In some embodiments, the release substrate is a soft silicone pad. In certain preferred embodiments, the compression step is carried out by placing the fiber membrane and the sacrificial substrate between two silicone pads placed on a solid surface, wherein the only compression is produced by the weight of the silicone pad placed on top of it.

[0059] In some embodiments, additional compressive force can be applied by using the pressure applied by placing heavier and heavier objects on the top of the silicone pad. In some embodiments, the pressure applied to the fiber membrane and the sacrificial substrate in the compression process is less than 25 psi, less than 20 psi, less than 18 psi, less than 15 psi, less than 12 psi, less than 10 psi, less than 8 psi, less than 7 psi, less than 6 psi, less than 5 psi, less than 4 psi, less than 3 psi, less than 2 psi, less than 1 psi, less than 0.5 psi, less than 0.4 psi, less than 3 psi, less than 2 psi or less than 0.1 psi. In some preferred embodiments, when applying pressure in the presence of heat, the pressure is 0.05 psi to 2 psi, 0.05 psi to 1 psi or 0.1 to 0.8 psi. In some further embodiments, the pressure applied during the compression process is 0.5-5 psi, 2-8 psi, 5-14 psi, 3-7 psi or 18-25 psi.

[0060] In some embodiments, manufacturing post-processing includes exposing the fiber membrane to a solvent to promote partially softened or swollen fibers to be welded together at their intersections. The solvent used for solvent welding should be able to soften or swell the fibers of the fiber membrane material at least in part to promote the fibers to be welded together within a reasonable amount of time. In some embodiments, the solvent is non-toxic. In other embodiments, the solvent has a solubility parameter similar to the Hildebrand material used to form the electrospun fiber membrane. In the case where a given concentrated solvent may dissolve quickly and destroy the morphology of the fiber of the fiber membrane, the solvent can be mixed with one or more non-solvents to provide a diluted solvent formulation that can provide controlled swelling and welding of the fiber without destroying the morphology of these fibers. In some embodiments, the solvent is selected from one or more of acetone, methyl ethyl ketone, dimethylacetamide, ethyl acetate, methyl acetate, N-methyl pyrrolidone, propylene carbonate, lactic acid esters, ether, methylene chloride, tetrahydrofuran, ethanol and methanol. In some embodiments, the solvent is acetone in a concentrated form, such as a formulation close to 100% pure acetone (NEAT). In some embodiments, the acetone is diluted with a polar non-solvent (such as isopropanol) to provide a formulation comprising 20-80% acetone. In certain embodiments, the acetone has been diluted to a concentration of 50% or 25%.

[0061] The method of applying the solvent to the fiber membrane is not particularly limited, as long as the solvent is applied relatively uniformly to at least one side of the fiber membrane. In some embodiments, the solvent can be applied to the fiber membrane before the fiber membrane contacts the sacrificial substrate. In some embodiments, the fiber membrane is saturated with acetone. Saturating the fiber membrane with the solvent can be performed by soaking, dipping or spraying in combination with a duration that allows saturation. In some embodiments, it is not desirable to saturate the fiber membrane with the solvent. In these cases, a limited amount of solvent can be applied to the surface of the fiber membrane, such as by spraying. In some embodiments, each 100cm2 0.5-10 mL of solvent is applied to the fiber membrane. In some embodiments, every 100 cm 2 Apply 0.5-1.5 mL, 1.0-2.5 mL, 2.0-4.0 mL, 3.0-4.5 mL, 4.0-5.5 mL, 5.0-6.5 mL, 6.0-7.5 mL, 7.0-8.5 or 8.0-9.5 mL of solvent to the fiber membrane.

[0062] In some embodiments, solvent welding is accompanied by applying compression to further promote the induction of the morphological change of the fiber membrane when it is applied to the sacrificial substrate and / or enhance the welding between the fibers of the fiber membrane. The specific pressure used in the compression step to promote the morphological change of the membrane and the welding of the fibers together can be any pressure disclosed herein and is not particularly limited, as long as the pressure does not cause the substrate to which the fiber membrane is applied to collapse. In some embodiments, compression is used in combination with solvent welding and comprises a compressive force of at least 0.1-25 Newtons, which is generated by compressing the relative release substrate that clamps the fiber membrane and the sacrificial substrate to which the fiber membrane is applied.

[0063] In some embodiments, applying compression during the manufacturing rear solvent welding step can reduce the time required for the firm welding between the fibers. The specific time required for giving firm welding under compression is not particularly limited and includes the duration as disclosed herein. In some embodiments, the fiber membrane is exposed to pressure and / or solvent for at least 30 seconds, 45 seconds, 60 seconds, 75 seconds, 90 seconds, 105 seconds, 120 seconds, 2.5 minutes, 3 minutes, 3.5 minutes, 4 minutes, 4.5 minutes, 5 minutes, 5.5 minutes, 6 minutes, 6.5 minutes, 7 minutes, 7.5 minutes, 8 minutes, 8.5 minutes, 9 minutes, 9.5 minutes, 10 minutes or longer.

[0064] In some embodiments, post-manufacturing treatment comprises physical or chemical crosslinking of the fibers. In some embodiments, the crosslinking is achieved by exposure to ultraviolet light, gamma radiation or plasma, by incorporating one or more crosslinking agents, or a combination thereof. The crosslinking agents that can be used to promote crosslinking of the fibers are not particularly limited, but include crosslinking agents that induce the formation of covalent bonds between compounds present in adjacent fibers. In some cases, the crosslinking agent includes glyoxal, isocyanate, glutaraldehyde, formaldehyde, carbodiimide, epoxide, citric acid, tannin, ferulic acid, glyceraldehyde, genepin, or transglutaminase.

[0065] In some embodiments, manufacturing post-processing changes the morphology and / or enhances the mechanical properties of the fiber membrane. The enhanced mechanical properties may include, but are not limited to, one or more of enhanced tensile strength, enhanced tensile modulus, enhanced wear resistance, enhanced thermal stability, enhanced elongation at break, enhanced hardness, and enhanced crystallinity. The change in morphology includes, but is not limited to, one or more of increased fiber diameter, reduced fiber diameter, increased porosity, reduced porosity, increased pore tortuosity, and reduced pore tortuosity.

[0066] In some embodiments, once the sacrificial material is completely surrounded by the fibrous membrane, the device can be further modified with additional channel networks or other tissue materials that may or may not contain cells. Next, the vascular network is formed by removing the sacrificial material, thereby creating a device consisting of (1) an empty lumen that may or may not contain one or more hierarchical channel networks completely surrounded by (2) a fibrous basement membrane that separates the vascular network from (3) an adjacent bulk tissue or channel network.

[0067] The fibrous membrane comprises fibers, preferably nanofibers, which are randomly arranged or have a specific orientation and are produced in a nonwoven manner, preferably by electrospinning.

[0068] In some embodiments, the fibers include a single material or a blend of materials such as from gelatin, gelatin complexes, collagen, fibrin, chitosan, nitrocellulose, polylactic acid, polycaprolactone, polyethylene glycol, polyethylene glycol diacrylate or other biopolymers, polymers, or decellularized tissue or extracellular matrix that has been liquefied or homogenized. In a preferred embodiment, the fibers include a combination of gelatin and polycaprolactone.

[0069] When fabricated into nanofibers, these materials can exhibit highly desirable mechanical properties and are strong enough to form thin films capable of withstanding physiological stresses. The composition of the nanofiber membranes also allows for highly controlled porosity, which can be used for filtration, diffusion, or other such transport of specific molecules while excluding other molecules based on size. This enables a variety of functional modules, including immune sensing and response.

[0070] In some embodiments, the fiber membrane is produced by electrospinning the fiber directly onto a sacrificial material or template that forms a vascular network. This can be achieved in a uniform manner by changing the electric field of the system (including adjusting the voltage, current and polarity of the nozzle, collector, sacrificial material and auxiliary guide). Similar results can also be achieved by dipping, spraying or otherwise adhering a fiber layer suspended in a solution / solvent to a sacrificial material or template that forms a vascular network.

[0071] Additional examples of the invention include devices wherein the sacrificial material is PVA, BVOH, Poloxomers P407, sucrose, or other water soluble sacrificial materials. In particular, water soluble sacrificial materials include water soluble polyurethanes. Particularly contemplated are those that are non-toxic to human renal fibroblasts and can be maintained at room temperature or 37 ℃ A water-soluble polyurethane that dissolves rapidly in water at neutral pH without appreciable swelling.

[0072] Additional examples of the invention include devices wherein the tissue material is gelatinmethacryol, fibrin, collagen, methylcellulose, homogenized extracellular matrix, or other materials.

[0073] Additional examples of the invention include devices where multiple constructs or components are assembled and functionally coupled together by depositing additional film material, ultrasonic welding, solvent bonding, adhesives, or other techniques such that they form a continuous base film throughout all constructs or components.

[0074] Additional examples of the invention include films as described in previous examples containing hydrogels, polymers, and compounds that have been modified by the addition of reinforcing agents or compounds to produce materials with tunable mechanical and biological properties.

[0075] Additional examples of the invention include films as described in previous examples, wherein the film is made using a multi-step process to create a film with a hybrid composition or architecture.

[0076] Additional examples of the invention include membranes as described in previous examples, containing hydrogels and polymers to which biological factors are encapsulated or added to promote cell and tissue growth.

[0077] It will be readily appreciated by those skilled in the art that the present invention is fully adapted to perform the objectives and obtain the results and advantages mentioned and inherent therein. The description details and examples herein represent certain embodiments, are exemplary, and are not intended to be limitations on the scope of the present invention. Modifications and other uses therein will be appreciated by those skilled in the art. These modifications are encompassed within the spirit of the present invention. It will be apparent to those skilled in the art that different substitutions and modifications may be made to the present invention disclosed herein without departing from the scope and spirit of the present invention.

[0078] Unless explicitly indicated to the contrary, the article "a (kind)" as used herein in the specification and in the claims should be understood to include plural (kind) indicators. Unless otherwise indicated or otherwise obvious from the context, if one, more than one or all group members are present, used in a given product or process, or otherwise related to a given product or process, then the claims or descriptions including "or" between one or more members of the group are considered to be consistent. The present invention includes embodiments in which exactly one member of the group is present, used in a given product or process, or otherwise related to a given product or process. The present invention also includes embodiments in which more than one or all group members are present, used in a given product or process, or otherwise related to a given product or process. In addition, it should be understood that unless otherwise indicated or unless it will be obvious to a person of ordinary skill in the art that a contradiction or inconsistency will occur, the present invention provides all variations, combinations and arrangements in which one or more limitations, elements, clauses, descriptive terms, etc. from one or more of the listed claims are introduced into another claim that is subordinate to the same basic claim (or any other claim when relevant). It is contemplated that, when appropriate, all embodiments described herein can be applied to all different aspects of the present invention. It is also contemplated that, whenever appropriate, any embodiment or aspect can be freely combined with one or more other such embodiments or aspects. When an element is presented in a list form, such as in a Markush group or similar form, it should be understood that each subgroup of the element is also disclosed, and any one or more elements can be removed from the group. It should be understood that, in general, in the case where the present invention or aspects of the present invention are referred to as comprising specific elements, features, etc., some embodiments of the present invention or aspects of the present invention are composed of such elements, features, etc. or are substantially composed of such elements, features, etc. For simplicity, those embodiments are not specifically described in this article with so many words in each case. It should also be understood that any embodiment or aspect of the present invention can be explicitly excluded from the claims, regardless of whether a specific exclusion is described in the specification. For example, any one or more active agents, additives, ingredients, optional agents, types of organisms, illnesses, subjects, or combinations thereof can be excluded.

[0079] When a claim or description refers to a composition of matter, it is understood that methods of making or using the composition of matter according to any method disclosed herein and methods of using the composition of matter for any purpose disclosed herein are aspects of the invention, unless otherwise indicated or unless it would be obvious to one of ordinary skill in the art that a contradiction or inconsistency would arise. When a claim or description refers to, for example, a method, it is understood that methods of making a composition useful for performing the method and products produced according to the method are aspects of the invention, unless otherwise indicated or unless it would be obvious to one of ordinary skill in the art that a contradiction or inconsistency would arise.

[0080] When a range is given in this article, the present invention includes embodiments including endpoints, embodiments excluding two endpoints, and embodiments including one endpoint and excluding another endpoint. Unless otherwise indicated, it should be assumed that two endpoints are included. In addition, it should be understood that unless otherwise indicated or otherwise apparent from the context and the understanding of a person of ordinary skill in the art, in different embodiments of the present invention, the value expressed as a range may be expressed as any specific value or sub-range within the stated range, reaching one-tenth of the lower limit unit of the range, unless the context clearly specifies otherwise. It should also be understood that when a series of numerical values ​​is stated in this article, the present invention includes embodiments similarly involving any interpolated values ​​or ranges defined by any two values ​​in the series, and the lowest value may be taken as the minimum value, and the maximum value may be taken as the maximum value. Numerical values ​​as used herein include values ​​expressed as percentages. For any embodiment of the present invention in which a numerical value begins with "about" or "approximately", the present invention includes embodiments in which the exact value is narrated. For any embodiment of the present invention in which a numerical value does not begin with "about" or "approximately", the present invention includes embodiments in which the value begins with "about" or "approximately".

[0081] As used herein, "A and / or B," where A and B are different claim terms, generally means at least one of A, B, or both A and B. For example, a sequence that is complementary to and / or hybridizes with another sequence includes: (i) a sequence that is complementary to another sequence, even if the one sequence does not necessarily hybridize to the other sequence under all conditions, (ii) a sequence that hybridizes to another sequence, even if the one sequence is not completely complementary to the other sequence, and (iii) a sequence that is both complementary to and hybridizes with another sequence.

[0082] "About" or "about" generally includes values ​​that fall within 1% in either direction (greater or less than the stated value) or in some embodiments fall within 5% of the value or in some embodiments fall within 10% of the value, unless otherwise indicated or otherwise obvious from the context (unless such a number would impermissibly exceed 100% of the possible values). It should be understood that, unless explicitly indicated to the contrary, in any method claimed herein that includes more than one action, the order of the actions of the method is not necessarily limited to the order in which the actions of the method are described, but the invention includes embodiments in which the order is so limited. It should also be understood that, unless otherwise indicated or obvious from the context, any product or composition described herein can be considered "isolated".

[0083] As used herein, the term "comprising" or includes when used in reference to compositions, methods, and one or more of their respective components essential to the invention is nevertheless an open-ended term that includes unspecified elements, whether or not the elements are essential.

[0084] As used herein, the term "consisting essentially of" refers to those elements required for a given embodiment. The term permits the presence of additional elements that do not materially affect one or more basic and novel or functional characteristics of the embodiment of the invention.

[0085] The term "consisting of" means that the compositions, methods, and corresponding components thereof as described herein do not include any elements not recited in the description of the embodiment.

[0086] Example

[0087] Example 1

[0088] Fabrication of fiber basement membrane

[0089] The vascular constructs with the desired hierarchical branching vascular channel architecture were fabricated by extrusion 3D printing using sacrificial materials made of water-soluble polyurethane.

[0090] A mixture of gelatin and polycaprolactone (PCL) (weight ratio of 1:1) was then dissolved in a solvent containing 8 parts of acetic acid and 1 part of formic acid to achieve a final concentration of 9%wt gelatin and 9%wt PCL.

[0091] The vascular structure made of the sacrificial material is then mounted into an electrospinning machine on a motorized stage. Gelatin and PCL solutions are loaded into the system and fibers are generated by standard electrospinning conditions, with voltages ranging from 8000-20000 volts and currents ranging from 0.1-50 mA. The fluid flow rate depends on the number and configuration of the nozzles. The scanning, rotation, and reorientation of the sacrificial material of the vascular channel are combined with the electrospinning configuration to create a complete continuous membrane coating. In a process called "bipolar electrospinning," the electric field is additionally manipulated by using oppositely charged nozzles facing each other to allow complete circumferential coating of the sacrificial material. Once the sacrificial material is completely coated, the construct is removed from the electrospinning system. The complete construct has an exposed outer membrane surface and an inner vascular surface in contact with the sacrificial material.

[0092] Additional sacrificial material is then deposited onto the outer membrane surface of the membrane material to create a network of epithelial channels or spaces.

[0093] A secondary solution of 17% by weight gelatin in phosphate buffered saline was then prepared.

[0094] This secondary solution is deposited into the mold, the vascular pattern and associated membrane are added to the surface of the solution, and a second volume of solution is added to the mold so that the vascular pattern and membrane material are completely encapsulated in the tissue solution.

[0095] The tissue solution was then cross-linked by adding transglutaminase (10 U / g gelatin) and allowed to solidify at 4°C for 24 h, resulting in a single tissue construct containing a stratified vascular network surrounded by a network of epithelial channels, with a fibrous basement membrane completely outlining the interface between the two.

[0096] Example 2

[0097] The goal of the experiment is to generate tube structures (supported and unsupported) of known dimensions according to the following steps:

[0098] A 3 mm ID mandrel is placed in the mold with or without the fiber support tube in place.

[0099] Then 12.5% ​​by weight gelatin solution was filled into the mold and cured at 4 °C for 1 h.

[0100] The mandrel together with the gelatin structure is then removed from the mold.

[0101] The gelatin structure was then removed from the mandrel and placed in a solution containing 10 U of transglutaminase for 1 hour at room temperature.

[0102] The gelatin construct was mounted on the barbed wire connector and secured in place with silk sutures.

[0103] Cap one end of the gelatin tube and connect one end to the pressure sensor and syringe.

[0104] The syringe barrel was compressed at a rate equal to 50 ml / min until rupture occurred and data was collected using a pressure transducer.

[0105] Table 1:

[0106]

Claims

1. A device comprising one or more channels defining a luminal space, wherein the luminal space is defined by an inner wall of a fibrous basement membrane material.

2. The device of claim 1, wherein the one or more channels form a vascular channel network.

3. The apparatus of claim 2, wherein the vascular channel network has a first end configured to be in fluid communication with a fluid supply port and a second end configured to be connected in fluid communication with a fluid outlet port.

4. The device of any one of claims 1-3, further comprising a scaffold material contacting an outer wall of the fibrous base membrane material.

5. The device of claim 4, wherein the scaffold material comprises one or more additional vascular channel networks, the one or more additional vascular channel networks optionally being defined by an inner wall of a fibrous basement membrane material.

6. The device of any one of claims 4-5, wherein the scaffold material comprises cells or bulk tissue.

7. The device of any one of claims 4-6, wherein the mechanical strength of the scaffold material is insufficient to define the luminal space without the support of the fibrous basement membrane material.

8. The device of any one of claims 1-7, wherein the inner wall of the fibrous basement membrane material inhibits or prevents the subject's immune response to cells and other substances in the luminal space when implanted in the subject.

9. The device of any one of claims 1-8, wherein the fibrous base membrane material comprises pores of sufficient size to enable diffusion of one or more biologically relevant molecules.

10. The device of any one of claims 1-9, wherein the one or more channels are capable of withstanding an internal pressure of at least 60 mmHg.

11. The device of any one of claims 2-10, wherein the vascular channel network is capable of withstanding an internal pressure of at least 60 mmHg.

12. The device as described in any one of claims 1-11, wherein the fibrous basement membrane material comprises one or more of gelatin, gelatin complex, collagen, fibrin, chitosan, nitrocellulose, polylactic acid, polycaprolactone, polyethylene glycol, polyethylene glycol diacrylate or other biopolymers, polymers or decellularized tissues or extracellular matrices that have been liquefied or homogenized.

13. The apparatus of any one of claims 1-12, wherein the fibrous base membrane material comprises electrospun fibers.

14. The device of any one of claims 1-12, wherein the fibrous basement membrane material comprises electrospun fibers, the electrospun fibers comprising a first component selected from the group consisting of polycaprolactone, polyethylene glycol and polyethylene glycol diacrylate, and a second component selected from the group consisting of gelatin, collagen and fibrin, and wherein the thickness of the fibrous basement membrane is 0.5-30 microns.

15. The device of any one of claims 1-14, wherein the fibrous base membrane material has been subjected to one or more post-manufacturing treatments selected from compression, annealing, chemical cross-linking, stretching, drawing, heat treatment and solvent welding, thereby imparting enhanced mechanical properties to the treated fibrous base membrane material compared to a fibrous base membrane material that has not undergone one or more of these post-manufacturing treatments.

16. The device of claim 15, wherein the enhanced mechanical property is selected from the group consisting of enhanced tensile strength, enhanced tensile modulus, enhanced wear resistance, enhanced thermal stability, enhanced elongation at break, enhanced hardness, enhanced crystallinity, and combinations thereof.

17. The apparatus of any one of claims 15-16, wherein the post-manufacturing process comprises solvent welding.

18. The apparatus of claim 17, wherein the solvent welding is performed in the presence of pressure imparted by an opposing support substrate.

19. The apparatus of any one of claims 15-16, wherein the post-fabrication treatment comprises a combination of heat treatment and pressure imparted by an opposing support substrate.

20. The device of any one of claims 1-19, wherein the device is implanted in a subject.

21. The device of any one of claims 1-19, wherein the device is located outside the body of the subject.

22. The device of any one of claims 1-21, wherein the luminal space comprises one or more cells selected from endothelial cells, epithelial cells, mesenchymal cells, induced pluripotent stem cell-derived cells, endocrine cells, and stromal cells.

23. The device of any one of claims 1-22, wherein the device is configured to function as an artificial kidney, pancreas, lung, myocardium, liver, spleen, small intestine, large intestine, neural tissue, skeletal muscle, composite tissue, adipose tissue, bone tissue, or skin.

Citation Information

Cited By

  • Multi-cell barrier tissue model of bionic sequential development mechanism

    CN121086973A